There are few phrases more comforting to investors than “raises full-year earnings guidance.”
They suggest management has found something encouraging in the numbers. Better margins. Stronger demand. Costs behaving themselves for once.
On Friday morning, Humana delivered precisely that headline.
The health insurer increased its 2026 adjusted earnings guidance from at least $9.00 to at least $9.50 per share.
Its GAAP earnings guidance received an even more dramatic promotion, jumping from at least $6.52 to at least $15.09 per share.
An $8.57 increase in the GAAP forecast.
Very impressive.
Until you look at the quarter.
According to Humana’s November 6 earnings release, the company earned $1.33 per share under generally accepted accounting principles during the third quarter.
On an adjusted basis, it lost $0.70 per share.
A year earlier, adjusted earnings were $3.24 per share.
That’s a $3.94 deterioration in quarterly adjusted EPS.
So how does a company report a substantially weaker adjusted quarter while raising its annual earnings forecast?
That’s the question worth investigating.
The Earnings Reconciliation Is Doing Some Heavy Lifting
Start with the third-quarter numbers.
Humana reported GAAP pretax income of $216 million.
After the company’s non-GAAP adjustments, that became an adjusted pretax loss of $104 million.
The largest individual reconciliation item was a $358 million negative adjustment related to put/call valuation changes associated with minority interests in its healthcare investments.
The adjustment removes a noncash valuation benefit from GAAP earnings.
That distinction matters.
The GAAP result includes a valuation effect that management excludes when assessing underlying performance.
Neither measure should be ignored.
GAAP earnings reflect the accounting consequences of the company’s transactions and obligations.
Adjusted earnings attempt to isolate results that management considers more representative of ongoing operations.
The problem begins when readers assume those two measures answer the same question.
They don’t.
A company can report positive GAAP earnings while producing an adjusted operating loss.
Humana just demonstrated that rather efficiently.
Revenue Growth Didn’t Rescue the Quarter
Humana’s consolidated third-quarter revenue increased from $32.65 billion in 2025 to $41.16 billion in 2026.
That’s approximately 26.1% growth.
An $8.51 billion increase in quarterly revenue would ordinarily attract considerable attention.
But revenue growth doesn’t establish that the additional business is equally profitable.
Humana’s insurance segment reported a GAAP operating loss of $303 million, compared with operating income of $251 million a year earlier.
That’s a $554 million deterioration.
On an adjusted basis, the insurance segment lost $299 million, compared with a $270 million profit in the prior-year quarter.
Meanwhile, Humana reported an insurance benefit ratio of 93.7%.
The ratio measures insurance benefits relative to the associated premium revenue. Higher benefit costs consume a larger portion of premiums, leaving less room for administration and profit.
Management said the ratio was favorable to its previous expectation of slightly above 94%.
That is useful evidence of performance relative to the company’s forecast.
But beating an internal expectation doesn’t automatically mean the underlying economics are attractive.
A loss can be better than expected and remain a loss.
Finance professionals generally understand this distinction.
Earnings headlines occasionally seem less enthusiastic about it.
The Full-Year Forecast Tells a Different Story
The raised adjusted guidance deserves closer examination.
Humana now expects at least $9.50 in adjusted earnings per share for 2026, compared with its previous expectation of at least $9.00.
That represents a minimum increase of approximately 5.6% relative to the previous guidance floor.
But the new forecast remains substantially below the $17.14 in adjusted EPS reported for 2025.
Using the guidance floor, that implies a year-over-year decline of at least 44.6% if actual 2026 adjusted EPS lands at exactly $9.50. Because the guidance is a minimum, the eventual decline could be smaller.
The company attributes the expected year-over-year deterioration partly to Medicare Advantage Star Ratings-related financial pressure.
And its GAAP guidance contains another important wrinkle.
Humana’s reconciliation includes a substantial negative adjustment for put/call valuation changes associated with minority investments, as well as an expected adjustment related to a new CenterWell joint venture.
The company also cautions that future changes in certain valuations cannot yet be reasonably estimated.
So the dramatic increase in GAAP EPS guidance should not be interpreted as an equivalent improvement in recurring operating earnings.
The adjusted guidance increase is considerably smaller.
And even that adjusted forecast still implies a difficult year compared with 2025.
The Forecasting Lesson Is Hiding in Plain Sight
There’s a familiar corporate finance problem buried in this earnings announcement.
Management can outperform a forecast without delivering strong absolute performance.
Suppose a business originally expects a $20 million operating loss.
It eventually loses $12 million.
That’s an $8 million favorable variance.
Finance can correctly report that the company performed better than planned.
But nobody should confuse the favorable variance with profitability.
The business still lost $12 million.
The same principle applies to earnings guidance.
When management raises a forecast, investors and finance teams should ask what changed.
Did customer demand improve?
Did unit economics strengthen?
Were costs permanently reduced?
Did the company recognize a favorable timing difference?
Were the original assumptions too pessimistic?
Or did accounting adjustments change the relationship between reported and adjusted results?
Those explanations have very different consequences for future earnings.
A sustainable improvement in medical cost trends could support a stronger long-term forecast.
A temporary valuation gain might improve reported GAAP results without changing the economics of insurance operations.
A one-time expense reduction might help the current year but offer little support for 2027.
The forecast needs to distinguish among them.
The CenterWell Deal Adds Another Layer
Humana also highlighted its strategic expansion of CenterWell Senior Primary Care.
The company reported year-to-date growth of 146,800 patients, approximately 30%.
It also announced a new joint venture with HPS Investment Partners, a BlackRock subsidiary, replacing previous arrangements with Welsh, Carson, Anderson & Stowe.
Management says the transaction is intended to improve balance-sheet efficiency, reduce the cost of capital, and provide additional financial flexibility.
Those are potentially meaningful benefits.
But the transaction also changes the company’s financial structure and introduces accounting consequences that complicate comparisons between reporting periods.
Humana disclosed that its September 30 balance sheet included approximately $1.2 billion in a net put liability associated with the previous partnerships, and that its guidance reconciliation reflects the reversal of that liability.
It also expects to recognize a new option liability associated with the BlackRock-related venture during the fourth quarter.
For CFOs evaluating similar arrangements, the lesson is worth remembering.
A transaction can improve capital flexibility while introducing new valuation exposure and changing reported earnings.
The financial model should separate operating performance, financing economics, accounting valuation effects, and cash consequences.
Otherwise, the business case may become a rather elaborate exercise in moving numbers between columns.
What CFOs Should Take From This
Humana’s earnings announcement offers a useful example of why guidance changes need their own reconciliation.
A raised forecast tells readers that management’s expectations have improved relative to its previous forecast.
It does not establish that the company’s year-over-year performance has improved.
Nor does it explain whether the improvement came from recurring operations, revised assumptions, accounting adjustments, or transaction-related effects.
For FP&A teams, the practical response is to build a bridge between the previous forecast and the new one.
Identify changes in operating volume, pricing, claims or other direct costs, administrative expenses, financing assumptions, and nonrecurring items.
Separate changes that affect cash from those that affect accounting earnings.
Then determine which improvements are likely to persist into the next planning period.
If the business raises its earnings forecast while underlying operating performance deteriorates, the reconciliation should make that tension visible.
A favorable variance is useful information.
It is not permission to stop asking questions.
The Headline Is Technically Correct. That’s Why the Footnotes Matter.
Humana did raise its earnings guidance.
That is a fact.
Its third-quarter adjusted earnings also deteriorated substantially from the prior year.
Another fact.
Revenue increased sharply, but the insurance segment reported an operating loss. GAAP earnings remained positive while adjusted earnings turned negative. And the company’s 2026 adjusted guidance remains well below its 2025 result.
All of those numbers belong in the same conversation.
The purpose of financial analysis is to understand how they fit together.
For CFOs, the most revealing question after a guidance increase isn’t simply how much the forecast improved.
It’s how much of that improvement reflects a stronger business.
Because management can raise the forecast, report a favorable variance, and still have a profitability problem.
The spreadsheet is perfectly capable of accommodating all three.
The earnings headline usually has room for only one.